Pasar al contenido principal

ESTRATEGIAS DE DIAGNOSTICO Y TRATAMIENTO EN ENFERMEDADES INFLAMATORIAS CRONICAS ARTICULARES Y DE LA PIEL

PID2021-124890OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Dehydroisohispanolone alleviates NLRP3-driven inflammation in gout arthritis.

  • González-Cofrade, Laura
  • Green, Jack P
  • de Las Heras, Beatriz
  • Terencio, María Carmen
  • Hortelano, Sonsoles
  • Brough, David
  • Estévez-Braun, Ana
  • Ferrándiz, María Luisa
  • Cuadrado, Irene
Natural products constitute an important resource for drug discovery with hispanolone derivatives recognized as bioactive diterpenes due to their broad therapeutic potential. Dehydroisohispanolone (DIH) is an anti-inflammatory labdane diterpene, that acts as a multi-target agent through various inflammation pathways. Aberrant activation of the Nod-like receptor protein 3 (NLRP3) inflammasome is involved in several inflammatory diseases, including gout. This study explores the mechanisms underlying the effects of DIH on the NLRP3 inflammasome and pyroptosis in vitro and evaluates its therapeutic effects on gouty arthritis in mice. DIH suppresses interleukin (IL)-1β secretion and pyroptosis in lipopolysaccharide (LPS)-primed bone-marrow-derived macrophages (BMDMs) elicited by broad stimuli. DIH exerts its action by disrupting adaptor apoptosis-associated speck-like protein (ASC) oligomerization, thereby inhibiting the assembly of inflammasome complex. Notably, DIH specifically inhibits NLRP3 inflammasome activation in murine BMDMs without affecting the absent in melanoma-2 (AIM2) or NOD-like receptor family CARD domain containing 4 (NLRC4) inflammasomes. In animal models, DIH significantly mitigated monosodium urate (MSU)-induced joint inflammation, reducing cytokine levels and myeloperoxidase (MPO) secretion. Overall, this study identified DIH as a specific inhibitor of the NLRP3 inflammasome, providing new insights into its potential as a therapeutic agent for NLRP3-mediated inflammatory diseases.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Adenosine A 2B receptor agonist improves epidermal barrier integrity in a murine model of epidermal hyperplasia

  • Marín-Castejón, A.
  • Marco-Bonilla, Miguel
  • Terencio Silvestre, Mª Carmen
  • Arasa, Jorge
  • Carceller, M. Carmen
  • Ferrándiz Manglano, María Luisa
  • Noguera, M. Antonia
  • Andres-Ejarque, Rosa
  • Montesinos-Mezquita, María Carmen
[EN] Adenosine regulates multiple physiological processes through the activation of four receptor subtypes, of which the A 2B adenosine receptor (A 2B AR) has the lowest affinity for adenosine. Being the adenosine receptor subtype most prominently expressed in epidermis, we recently described the antiproliferative and anti-inflammatory effect of the selective A 2B AR agonist BAY60 -6583 (BAY) in human keratinocytes stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA), so we sought to establish the effect of topical application of BAY in a model of murine epidermal hyperplasia. Topical application of BAY (1 or 10 mu g/site) prevented the inflammatory reaction and skin lesions induced by TPA, minimizing hyperproliferation and acanthosis, as well as the expression of specific markers of proliferative keratinocytes. On the other hand, pre-treatment with the selective A 2B AR antagonist, PSB-1115 (PSB, 5 or 50 mu g/ site) reversed these beneficial effects. Additionally, BAY application normalized the expression of epidermal barrier proteins, whose integrity is altered in inflammatory skin diseases, while treatment with the antagonist alone worsened it. Our results, besides confirming the anti-inflammatory and antiproliferative effects of the A2BAR agonist, further demonstrate a role of A 2B AR activation to preserve the epidermal barrier. Therefore, the activation of A 2B AR may constitute a possible new pharmacological target for the treatment of skin inflammatory diseases such as psoriasis., Supported by grants SAF2017-85806-R and PID2021-124890OB-I00 funded by Spain Government Ministry of Science, Innovation and Universities, MCIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe", by the "European Union".
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Cyclosporin A-loaded dissolving microneedles for dermatitis therapy: Development, characterisation and efficacy in a delayed-type hypersensitivity in vivo model

  • Martínez-Navarrete, Miquel
  • Guillot, Antonio Jose
  • Lobita, Maria C.
  • Recio, Maria Carmen
  • Giner, Rosa
  • Aparicio-Blanco, Juan
  • Montesinos-Mezquita, María Carmen
  • Santos, Helder A.
  • Melero, Ana
[EN] Several drugs can be used for treating inflammatory skin pathologies like dermatitis and psoriasis. However, for the management of chronic and long-term cases, topical administration is preferred over oral delivery since it prevents certain issues due to systemic side effects from occurring. Cyclosporin A (CsA) has been used for this purpose; however, its high molecular weight (1202 Da) restricts the diffusion through the skin structure. Here, we developed a nano-in-micro device combining lipid vesicles (LVs) and dissolving microneedle array patches (DMAPs) for targeted skin delivery. CsA-LVs allowed the effective incorporation of CsA in the hydrophilic DMAP matrix despite the hydrophobicity of the drug. Polymeric matrix composed of poly (vinyl alcohol) (5% w/v), poly (vinyl pyrrolidine) (15% w/v) and CsA-LV dispersion (10% v/v) led to the formation of CsA-LVs@DMAPs with adequate mechanical properties to penetrate the stratum corneum barrier. The safety and biocompatibility were ensured in an in vitro viability test using HaCaT keratinocytes and L929 fibroblast cell lines. Ex vivo permeability studies in a Franz-diffusion cell setup showed effective drug retention in the skin structure. Finally, CsA-LVs@DMAPs were challenged in an in vivo murine model of delayed-type hypersensitivity to corroborate their potential to ameliorate skin inflammatory conditions. Different findings like photon emission reduction in bioluminescence study, normalisation of histological damage and decrease of inflammatory cytokines point out the effectivity of CsA-LVs@DMAPs to treat these conditions. Overall, our study demonstrates that CsA-LVs@DMAPs can downregulate the skin inflammatory environment which paves the way for their clinical translation and their use as an alternative to corticosteroid-based therapies., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This publication is part of the grants PID2020-114530GA-I00 (to A.M.) and PID2021-124890OB-I00 (to M.C.M.) funded by MCIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe", by the "European Union". H.A.S. acknowledges financial support from the UMCG Research Funds and the Academy of Finland (grant no. 331151). M.M-N acknowledges the financial support from ACIF grant funded by Generalitat Valenciana; Conselleria d'Innovacio, Universitats, Ciencia i Societat Digital (ref: CIACIF/2022/341). A.J.G. acknowledges the financial support from "Margarita Salas" grant (ref: MS21-126) funded by the Spanish Ministry of Universities and European Union (Next generation-EU).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

New Insights into the Pro-Inflammatory and Osteoclastogenic Profile of Circulating Monocytes in Osteoarthritis Patients

  • Guillem-Llobat, Paloma
  • Marín, Marta
  • Rouleau, Matthieu
  • Silvestre, Antonio
  • Blin-Wakkach, Claudine
  • Guillén, Maria Isabel
  • Ibáñez, Lidia
  • Vercher Ferrandiz, Mª Luisa|||0000-0002-1822-5158
[EN] Osteoarthritis (OA) is a degenerative condition of the articular cartilage with chronic low-grade inflammation. Monocytes have a fundamental role in the progression of OA, given their implication in inflammatory responses and their capacity to differentiate into bone-resorbing osteoclasts (OCLs). This observational-experimental study attempted to better understand the molecular pathogenesis of OA through the examination of osteoclast progenitor (OCP) cells from both OA patients and healthy individuals (25 OA patients and healthy samples). The expression of osteoclastogenic and inflammatory genes was analyzed using RT-PCR. The OA monocytes expressed significantly higher levels of CD16, CD115, TLR2, Mincle, Dentin-1, and CCR2 mRNAs. Moreover, a flow cytometry analysis showed a significantly higher surface expression of the CD16 and CD115 receptors in OA vs. healthy monocytes, as well as a difference in the distribution of monocyte subsets. Additionally, the OA monocytes showed a greater osteoclast differentiation capacity and an enhanced response to an inflammatory stimulus. The results of this study demonstrate the existence of significant differences between the OCPs of OA patients and those of healthy subjects. These differences could contribute to a greater understanding of the molecular pathogenesis of OA and to the identification of new biomarkers and potential drug targets for OA., This research was funded by Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, grant number GV/2020/136; Ministerio Ciencia e Innovación, grant number PID2021-124890OB-I00; CEU Universities and Banco Santander, grant number FUSPBS-PPC07/2018; and Cardenal Herrera-CEU University, grant numbers INDI 18/22, INDI20/24, INDI21/27, and INDI22/28.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Osteostatin Mitigates Gouty Arthritis through the Inhibition of Caspase-1 Activation and Upregulation of Nrf2 Expression

  • Catalán, Laura
  • Carceller, Maria Carmen
  • Terencio Silvestre, Mª Carmen
  • Alcaraz Tormo, Mª Jose
  • Ferrándiz Manglano, María Luisa
  • Montesinos-Mezquita, María Carmen
[EN] Gouty arthritis results from monosodium urate (MSU) crystal deposition in joints, initiating (pro)-interleukin (IL)-1 beta maturation, inflammatory mediator release, and neutrophil infiltration, leading to joint swelling and pain. Parathyroid hormone-related protein (107-111) C-terminal peptide (osteostatin) has shown anti-inflammatory properties in osteoblasts and collagen-induced arthritis in mice, but its impact in gouty arthritis models remains unexplored. We investigated the effect of osteostatin on pyroptosis, inflammation, and oxidation in macrophages, as well as its role in the formation of calcium pyrophosphate dihydrate crystals and MSU-induced gouty arthritis in mice models. Osteostatin ameliorated pyroptosis induced by lipopolysaccharide and adenosine 5 '-triphosphate (LPS + ATP) in mice peritoneal macrophages by reducing the expression of caspase-1, lactate dehydrogenase release, and IL-1 beta and IL-18 secretion. Additionally, IL-6 and tumor necrosis factor-alpha (TNF-alpha) were also decreased due to the reduced activation of the NF-kappa B pathway. Furthermore, osteostatin displayed antioxidant properties in LPS + ATP-stimulated macrophages, resulting in reduced production of mitochondrial and extracellular reactive oxygen species and enhanced Nrf2 translocation to the nuclei. In both models of gouty arthritis, osteostatin administration resulted in reduced pro-inflammatory cytokine production, decreased leukocyte migration, and reduced caspase-1 and NF-kappa B activation. These results highlight the potential of osteostatin as a therapeutic option for gouty arthritis., This study was supported by grants SAF2017-85806-R and PID2021-124890OB-I00 funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe from the European Union .
Docta Complutense
Publicación Artículo científico (JournalArticle)

Dehydroisohispanolone alleviates NLRP3-driven inflammation in gout arthritis

  • González Cofrade, Laura
  • J. P. Green
  • Heras Polo, Beatriz De Las
  • Terencio, Carmen
  • Hortelano, Sonsoles
  • Brough, David
  • Estévez-Braun, Ana
  • Ferrándiz, Laría Luisa
  • Cuadrado Berrocal, Irene
Natural products constitute an important resource for drug discovery with hispanolone derivatives recognized as bioactive diterpenes due to their broad therapeutic potential. Dehydroisohispanolone (DIH) is an anti-inflammatory labdane diterpene, that acts as a multi-target agent through various inflammation pathways. Aberrant activation of the Nod-like receptor protein 3 (NLRP3) inflammasome is involved in several inflammatory diseases, including gout. This study explores the mechanisms underlying the effects of DIH on the NLRP3 inflammasome and pyroptosis in vitro and evaluates its therapeutic effects on gouty arthritis in mice. DIH suppresses interleukin (IL)-1β secretion and pyroptosis in lipopolysaccharide (LPS)-primed bone-marrow-derived macrophages (BMDMs) elicited by broad stimuli. DIH exerts its action by disrupting adaptor apoptosis-associated speck-like protein (ASC) oligomerization, thereby inhibiting the assembly of inflammasome complex. Notably, DIH specifically inhibits NLRP3 inflammasome activation in murine BMDMs without affecting the absent in melanoma-2 (AIM2) or NOD-like receptor family CARD domain containing 4 (NLRC4) inflammasomes. In animal models, DIH significantly mitigated monosodium urate (MSU)-induced joint inflammation, reducing cytokine levels and myeloperoxidase (MPO) secretion. Overall, this study identified DIH as a specific inhibitor of the NLRP3 inflammasome, providing new insights into its potential as a therapeutic agent for NLRP3-mediated inflammatory diseases.